LAS VEGAS, Oct. 23, 2025 -- In a field where scientific validation defines credibility, Synbio Tech Inc., a biotechnology company from Taiwan, is gaining international recognition with its proprietary probiotic Lactiplantibacillus plantarum TWK10®. The clinically proven strain, which will be featured at SupplySide Global 2025 from October 27–30 (Booth #6253F), has shown measurable benefits on muscle strength, endurance, and balance—offering a new microbiome-based approach to healthy aging and active living. Backed by over a decade of research, TWK10® has been evaluated
BEIJING, Oct. 22, 2025 -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be the largest antibody-drug conjugate (ADC) milestone payment among hundreds of out-licensing deals involving Chinese innovative drugs. Notably, the overall transaction had previously set a record for the total value of a single-drug asset license in China. In recent years, China's dynamic pharmaceutical ecosystem has rapidly emerged as one of the wo
— Second U.S. site to deploy the Reveos™ system, boosting platelet supply and reducing waste LAKEWOOD, Colo., Oct. 22, 2025 -- To help address platelet shortages and streamline blood center operations, The Blood Center in New Orleans has become the second U.S. blood center to implement the Reveos™ Automated Blood Processing System and the Lumia™ Software Platform from Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions. The move marks a significant step forward in transforming how blood centers process bl
The CathWorks FFRangio® System to be Center Stage, Featured in Multiple Scientific Sessions, Live Cases and a Primetime Academic Satellite Program NEWPORT BEACH, Calif., Oct. 22, 2025 -- CathWorks, a global leader in digital health innovations, announced today the schedule of key events for the company during the upcoming Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) conference taking place October 25 to 28 at the Moscone Center in San Francisco, California. The CathWorks FFRangio® System will be featured in multiple
SHANGHAI, NANJING, China and PLEASANTON, Calif., Oct. 22, 2025 -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, production, and commercialization of novel cell therapies, today announced that the Blood published the latest results of its independently developed fully human anti-GPRC5D CAR-T cell therapy, RD118, for the treatment of relapsed/refractory multiple myeloma (R/R MM). The study demonstrates that RD118 exhibited significant efficacy and a manageable safety profile in heavily pretreated R/R MM patients, offering new the
Striving for HK$5 million Donations to Help "Bring The Children Home" Campaign and Other Impactful Programmes for Children with Special Needs HONG KONG, Oct. 22, 2025 -- The Society for the Relief of Disabled Children (SRDC), one of the longest-standing NGOs in Hong Kong dedicated to supporting children with disabilities, proudly celebrates its 70th anniversary this year. Since its founding in 1955, SRDC develops into the forefront of providing life-changing care, research, advocacy, and resources to children with disabilities and their families. To mark this momentous
EAST RUTHERFORD, N.J., Oct. 22, 2025 -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S. operations, addressing increased demand for API development and manufacturing, and accelerating the company's leadership role in the fast-growing peptide therapeutics market. "Our customers, in partnership with federal and state agencies, are reshoring drug manufacturing in the U.S., the world's largest pharmaceutical market. Local API production is vital for supply chain security and resi
이스트러더퍼드, 뉴저지주, 2025년 10월 22일 -- 세계적인 의약품 위수탁개발생산(CDMO) 기업인 캠브렉스(Cambrex)가 오늘 미국 사세 확충 목적으로 1억 2000만 달러를 투자한다고 발표했다. 이는 증가하는 의약품원료(API) 개발 및 제조 수요에 대응하고 급성장 중인 펩타이드 치료제 시장에서 자사의 선도적 역할을 강화하고자 단행한 조치이다. 캠브렉스 CEO 토마스 로월드(Thomas Loewald)는 "고객사들이 정부 기관과 손잡고 세계 최대 제약 시장인 미국으로 의약품 제조 시설을 이전하는 추세이다. 공급망의 보안과 회복력을 유지하려면 현지 API 생산이 필수적인데, 캠브렉스는 그와 관련해 핵심적인 역할을 맡게 될 것이다. 실제로, 캠브렉스의 확충된 생산 시설을 활용하려는 고객사가 크게 늘고 있다"라고 전했다. 1억 2000만 달러 규모의 투자로 아이오와주 찰스 시티 공장의 대량 생산 능력이 40% 증가하여 약 100만 리터에 육박할 것으로 전망된다. 대지 면적이 약 18만 2000 제곱미터인 찰스 시티 공장에서는 고효능 분자와 규제 약물을 비롯해 다양한 API와 의
[ 메디채널 김갑성 기자 ] 홍콩 2025년 10월 22일 -- 2025년 쇼상(Shaw Prize) 시상식이 10월 21일 홍콩 컨벤션•전시센터 그랜드홀(Grand Hall of the Hong Kong Convention and Exhibition Centre)에서 열려 수상자 4인에게 상이 수여됐다. 이번 행사에는 각계각층에서 약 600명의 내빈이 참석해 자리를 빛냈다. 쇼상 위원회(The Shaw Prize Council) 위원장인 케네스 영(Kenneth Young) 교수는 개회사에서 쇼상 창립 멤버인 양전닝(Chen-ning Yang) 교수의 별세에 깊은 애도를 표했다. 영 교수는 양 교수가 창설 초기부터 상의 위상을 높이는 데 핵심적인 역할을 수행했으며, 상의 발전과 세계적 명성 확립에 지대한 영향을 미쳤음을 강조했다. 또한 영 교수는 쇼상재단(The Shaw Prize Foundation)을 대표해 양 교수의 유족과 친구들 및 전 세계 과학계에 깊은 애도의 뜻을 전했다. 이어 심사위원회 위원장 라인하르트 겐젤(Reinhard Genzel) 교수가 2025년 쇼상 수상자인 존 리처드 본드(John Ri
REUS, Spain, Oct. 22, 2025 -- Leading health researchers from around the world have identified new priorities and directions in nut and dried fruit research, highlighting the growing body of evidence linking their consumption to improved metabolic health, cardiovascular health, fertility, the immune system, bone health, and brain function. The experts also explored emerging findings on the gut microbiome and biomarkers of nut consumption. These findings emerged from the NUTS 2025 conference, held on October 9–10, 2025, and hosted by the International Nut and Dried Fruit Council (INC).